TB-500
Thymosin Beta-4 fragment
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring peptide that regulates actin — the protein scaffolding cells use to move. It's one of the two flagship 'healing peptides' (alongside BPC-157) and is researched for soft-tissue, tendon, muscle and cardiac repair, plus flexibility and recovery. This guide covers how TB-500 actually works, what the research does and doesn't show, how it's referenced in the literature, its safety and legal status (including its WADA ban in sport), and how it compares to and stacks with BPC-157.
TB-500 quick facts
| Reported research dosing | 2mg-5mg |
| Route | Subq |
| Cycle length | 4-12 Weeks |
| Frequency | 1-2x a Week |
| Half-life | ~2-3 hrs plasma (tissue effects last days; dosed 1-2x/wk) |
| Forms | Injectable, Nasal |
| Evidence level | Animal + anecdotal |
The systemic partner to BPC-157. Longer half-life means you don't need it daily.
How TB-500 works
TB-500's core mechanism is actin regulation. It's the main G-actin-sequestering peptide in cells: it binds monomeric actin and holds a ready reservoir that cells can rapidly deploy to build the filaments they need to migrate. That matters because healing depends on fibroblasts, keratinocytes and endothelial cells physically moving into injured tissue — and Tβ4 has been shown to stimulate keratinocyte migration 2–3 fold in research models.
Beyond actin, TB-500 promotes angiogenesis (new blood-vessel growth, partly via VEGF), exerts anti-inflammatory effects through NF-κB modulation, and appears to recruit stem/progenitor cells to damaged areas. The combination — cell migration + blood supply + reduced inflammation — is why it's studied so broadly across wound, tendon, muscle and heart tissue.
What the research shows — benefits by use case
Wound & soft-tissue healing. Animal models show faster wound closure, angiogenesis and keratinocyte migration — the best-established effect.
Tendon, muscle & flexibility. TB-500 is popular among athletes for recovery and a subjective sense of improved flexibility/mobility, thought to relate to its systemic cell-migration effects. Human evidence here is anecdotal rather than trial-proven.
Cardiac repair. In animal models, thymosin beta-4 reduced infarct size and improved cardiac function after heart attack — a striking preclinical signal that continues to drive research interest.
Honesty check: as with BPC-157, most TB-500 evidence is preclinical (animal/cell). It's mechanistically compelling but not the same as proven human efficacy.
The honest state of human evidence
The most advanced human work on thymosin beta-4 is topical, not injectable: the ophthalmic formulation RGN-259 reached Phase II trials for dry-eye and corneal healing with encouraging results. For the injectable, systemic use most people are interested in, robust human trial data is limited — the enthusiasm is built largely on animal studies plus athlete anecdote. Treat it as a promising research compound, not a proven therapy.
TB-500 dosing (research reference)
The research and practitioner literature commonly references TB-500 dosed weekly, often with a higher 'loading' phase for several weeks followed by a lower maintenance dose, reflecting its long systemic action (it doesn't need daily dosing the way BPC-157 often is). It's supplied as a lyophilized powder and reconstituted with bacteriostatic water — the reconstitution calculator above converts a research amount into syringe units. This summarizes existing references and is not dosing advice or a recommendation for human use.
Safety & side effects
In animal studies and anecdotal human reports, TB-500 is generally described as well tolerated, with few acute effects noted. But long-term human safety data is lacking, and — as with any peptide that promotes angiogenesis and cell migration — the mechanism is worth understanding rather than assuming it's risk-free. Research-market purity varies widely; a Certificate of Analysis and third-party testing matter.
BPC-157 vs TB-500 — and stacking
BPC-157 and TB-500 are the classic healing-peptide duo, and they work through different mechanisms: BPC-157 leans toward local vascular and gut repair (VEGF, nitric oxide), while TB-500 works more systemically via actin-driven cell migration and flexibility. Because their pathways are complementary, they're frequently run together — the basis of the popular Wolverine blend.
Legal & regulatory status
TB-500 is not FDA-approved and is sold as a research compound (research use only). Notably, thymosin beta-4 / TB-500 is on the WADA Prohibited List — it is banned in competitive sport at all times — so athletes subject to drug testing should be aware. Its compounding status, like other peptides, remains under ongoing FDA review. Follow the laws and rules that apply to you.
Human clinical evidence
- No randomised human trials. This is a research compound sold for laboratory use, and nobody has funded the trial that would change that — not because it failed one, but because there is no route to a return on it. Read the correlative and theoretical tiers as the actual evidence base rather than as a consolation prize.
📊 Correlative data
- Thymosin beta-4 — the full protein TB-500 is a fragment of — reached phase 2 human trials for dry eye and for pressure ulcers, and was tolerated. Those trials tested the parent molecule by a different route for different endpoints, so they establish that the biology is safe to touch in humans and very little else.
- Widely used alongside BPC-157 for soft-tissue injury; the reported pattern is slower onset and a broader, more systemic feel than BPC.
🧪 How the mechanism reads
- An actin-binding fragment. Its mechanism is cell migration — it promotes the movement of the cells that do repair work into the site that needs them, which is a genuinely different mechanism from BPC-157's angiogenic one and the reason the two are stacked rather than swapped.
- The same pro-migratory, pro-angiogenic signalling carries the same unanswerable long-term question as BPC-157.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
TB-500 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signalling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumour needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterised. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Close to the tissue, and consistency beats the clock
A brief exposure starts a process that runs for days, so the hour you dose is a minor variable — missing days is the one that costs you. Where the target is local, dosing near the site is worth more than any timing choice.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
TB-500 reconstitution calculator
Research reconstitution calculator
Where to get TB-500
Buy TB-500 at AminoWell USA →TB-500 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What TB-500 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for TB-500 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
Bloodwork to run alongside TB-500
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation before a recovery compound |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Complete Blood Count (CBC) with Differential | Platelets matter for any tissue-repair claim |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 102 markers A–Z
TB-500 — frequently asked questions
What is TB-500?
TB-500 is a synthetic fragment of thymosin beta-4, a natural peptide that regulates actin and cell migration. It's researched for soft-tissue, tendon, muscle and cardiac repair and recovery.
How does TB-500 work?
It sequesters G-actin to give cells a ready supply for building the filaments they need to migrate into injured tissue, and it also promotes angiogenesis (via VEGF), reduces inflammation (NF-κB), and recruits stem/progenitor cells.
Does TB-500 work in humans?
The most advanced human data is for a topical eye formulation (RGN-259, Phase II). For injectable systemic use, human trial evidence is limited and most support is animal studies plus athlete anecdote. Treat it as an experimental research compound.
How is TB-500 dosed?
The literature commonly references weekly dosing, often a higher loading phase for a few weeks then a lower maintenance dose, given its long systemic action. It's reconstituted with bacteriostatic water — use the calculator above. This is educational, not dosing advice.
BPC-157 vs TB-500 — which is better?
They do different jobs and are often combined rather than chosen between. BPC-157 focuses on local vascular/gut repair; TB-500 works systemically on cell migration and flexibility. The 'Wolverine' blend stacks both.
Is TB-500 banned in sport?
Yes. Thymosin beta-4 / TB-500 is on the WADA Prohibited List and is banned at all times in competitive sport. Tested athletes should be aware.
What are the side effects of TB-500?
Animal studies and anecdotal reports describe it as generally well tolerated, but long-term human safety data is lacking, and research-market purity varies — insist on third-party testing.
References & further reading
- TB-500 (thymosin beta-4): actin sequestration & cell-migration research
- TB-500 literature review & mechanisms
- TB-500 complete research guide (Path to Peptides)
Want Coach Cam's exact TB-500 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What TB-500 is used for
TB-500 appears under 3 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.